ES2049332T3 - Procedimiento para la reduccion de la heterogeneidad de los anticuerpos monoclonales. - Google Patents

Procedimiento para la reduccion de la heterogeneidad de los anticuerpos monoclonales.

Info

Publication number
ES2049332T3
ES2049332T3 ES89309851T ES89309851T ES2049332T3 ES 2049332 T3 ES2049332 T3 ES 2049332T3 ES 89309851 T ES89309851 T ES 89309851T ES 89309851 T ES89309851 T ES 89309851T ES 2049332 T3 ES2049332 T3 ES 2049332T3
Authority
ES
Spain
Prior art keywords
antibodies
heterogeneity
monoclonal antibodies
procedure
reduction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89309851T
Other languages
English (en)
Inventor
Richard Mark Bartholomew
Thomas Charles Furman
Rodney Alan Jue
James Patrick Mcdonough
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/364,056 external-priority patent/US5126250A/en
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of ES2049332T3 publication Critical patent/ES2049332T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

SE DESCUBREN NUEVOS METODOS PARA REDUCIR LA HETEROGENEIDAD DE ANTICUERPOS MONOCLONALES SEGREGADOS. EL PRIMER METODO COMPRENDE INCUBAR LOS ANTICUERPOS HETEROGENEOS A BAJO PH DURANTE UN PERIODO DE TIEMPO SUFICIENTE PARA CONVERTIR LAS FORMAS HETEROGENEAS DE ANTICUERPOS EN FORMAS SUBSTANCIALMENTE HOMOGENEAS. OTRO METODO PRODUCE EL MISMO RESULTADO USANDO ASCOCITOS LIQUIDO, MIENTRAS QUE TODAVIA OTRO METODO PRODUCE EL MISMO RESULTADO USANDO CARBOXIPEPTIDASA. LOS ANTICUERPOS HOMOGENEOS SE PUEDEN ENTONCES PURIFICAR CON GRAN RENDIMIENTO.
ES89309851T 1988-09-28 1989-09-27 Procedimiento para la reduccion de la heterogeneidad de los anticuerpos monoclonales. Expired - Lifetime ES2049332T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US25078888A 1988-09-28 1988-09-28
US25078788A 1988-09-28 1988-09-28
US25078688A 1988-09-28 1988-09-28
US07/364,056 US5126250A (en) 1988-09-28 1989-06-09 Method for the reduction of heterogeneity of monoclonal antibodies
CA000613379A CA1332367C (en) 1988-09-28 1989-09-26 Method for the reduction of heterogeneity of monoclonal antibodies

Publications (1)

Publication Number Publication Date
ES2049332T3 true ES2049332T3 (es) 1994-04-16

Family

ID=27508376

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89309851T Expired - Lifetime ES2049332T3 (es) 1988-09-28 1989-09-27 Procedimiento para la reduccion de la heterogeneidad de los anticuerpos monoclonales.

Country Status (17)

Country Link
EP (1) EP0361902B1 (es)
JP (1) JP2925181B2 (es)
CN (1) CN1041392A (es)
AR (1) AR242986A1 (es)
AT (1) ATE101876T1 (es)
AU (1) AU615576B2 (es)
BG (1) BG60017A3 (es)
CA (1) CA1332367C (es)
DE (1) DE68913251T2 (es)
DK (1) DK475389A (es)
ES (1) ES2049332T3 (es)
IE (1) IE63562B1 (es)
IL (1) IL91778A (es)
MX (1) MX170441B (es)
NZ (1) NZ230786A (es)
PL (1) PL162260B1 (es)
RO (1) RO105652B1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4001409A1 (en) 2006-03-31 2022-05-25 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
EP1878747A1 (en) 2006-07-11 2008-01-16 greenovation Biotech GmbH Glyco-engineered antibodies
EP2031064A1 (de) * 2007-08-29 2009-03-04 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Steigerung von Proteintitern
KR102467302B1 (ko) 2007-09-26 2022-11-14 추가이 세이야쿠 가부시키가이샤 항체 정상영역 개변체
DK2202245T3 (en) 2007-09-26 2016-11-21 Chugai Pharmaceutical Co Ltd A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR
EP3521311A1 (en) 2008-04-11 2019-08-07 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
TWI440469B (zh) * 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
US9228017B2 (en) 2009-03-19 2016-01-05 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
US20120071634A1 (en) 2009-03-19 2012-03-22 Chugai Seiyaku Kabushiki Kaisha Antibody Constant Region Variant
CA2819356C (en) 2010-11-30 2023-01-24 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
KR101903208B1 (ko) * 2010-12-28 2018-10-01 추가이 세이야쿠 가부시키가이샤 동물 세포의 배양 방법
NZ711445A (en) 2013-03-12 2018-06-29 Biocon Ltd Fusion immunomodulatory proteins and methods for making same
JP6442404B2 (ja) 2013-06-11 2018-12-19 国立研究開発法人国立精神・神経医療研究センター 再発寛解型多発性硬化症(rrms)患者の治療予後予測方法、及び新規治療適応判断方法
BR112017014067B1 (pt) 2015-02-27 2021-01-12 Chugai Seiyaku Kabushiki Kaisha usos de um anticorpo receptor de il-6 para no tratamento de doenças relacionadas a il-6
JP6875683B2 (ja) 2015-05-19 2021-05-26 国立研究開発法人国立精神・神経医療研究センター 多発性硬化症(ms)患者の新規治療適用判断方法
EP3500586B1 (en) * 2016-10-17 2021-02-24 Enzene Biosciences Ltd. Continuous process for reducing heterogeneity of therapeutic protein
WO2018203545A1 (ja) 2017-05-02 2018-11-08 国立研究開発法人国立精神・神経医療研究センター Il-6及び好中球の関連する疾患の治療効果の予測及び判定方法
EP3698808A4 (en) 2017-10-20 2021-07-14 Hyogo College Of Medicine MEDICAL COMPOSITION CONTAINING ANTI-IL-6 RECEPTOR ANTIBODIES FOR THE PREVENTION OF POSTOPERATIVE ADHESION

Also Published As

Publication number Publication date
AR242986A1 (es) 1993-06-30
BG60017A3 (en) 1993-06-15
PL162260B1 (pl) 1993-09-30
EP0361902A2 (en) 1990-04-04
JPH02163096A (ja) 1990-06-22
RO105652B1 (ro) 1992-11-30
ATE101876T1 (de) 1994-03-15
EP0361902A3 (en) 1990-08-16
DE68913251D1 (de) 1994-03-31
NZ230786A (en) 1991-11-26
DE68913251T2 (de) 1994-06-23
AU615576B2 (en) 1991-10-03
IE893094L (en) 1990-03-28
EP0361902B1 (en) 1994-02-23
CN1041392A (zh) 1990-04-18
DK475389A (da) 1990-03-29
CA1332367C (en) 1994-10-11
IL91778A (en) 1994-10-07
MX170441B (es) 1993-08-23
AU4234389A (en) 1990-04-05
IE63562B1 (en) 1995-05-17
JP2925181B2 (ja) 1999-07-28
DK475389D0 (da) 1989-09-27

Similar Documents

Publication Publication Date Title
ES2049332T3 (es) Procedimiento para la reduccion de la heterogeneidad de los anticuerpos monoclonales.
NO833100L (no) Fremgangsmaate for flytendegjoering av metan.
DE69727495D1 (de) Einteiliger verbundschichtstoff
ES2110230T3 (es) Ensayo de rapamicina.
ES2110993T3 (es) Anticuerpos monoclonales especificos para la toxina b de clostridium difficile.
ES521774A0 (es) Compuerta de gas mejorada para reducir sustancialmente la retrocirculacion de los gases.
ES460385A1 (es) Un procedimiento para preparar una 6a,10a-trans-hexahidrodi-benzo (b,d) piran-9-ona.
NO162179C (no) Monoklonale antistoffer for anvendelse in vitro.
DK526783A (da) Forbedret stamme af clostridium acetobutylicum og fremgangsmaade til fremstilling af samme
IT8323530V0 (it) Struttura di accendigas per uso domestico.
DK354987D0 (da) Fremgangsmaade til fremstilling af floursulfonamider
DK407987A (da) Apolipoprotein b-specifikke monoklonale antistoffer og hybridomer, som producerer disse antistoffer
OA07730A (fr) Perfectionnements apportés aux capteurs solaires.
DK327183A (da) Fremgangsmaade til udfoerelse af elektromikrobiel reduktion
JPS51133042A (en) Connecting method of light transmission fibers
ES2044893T3 (es) Un anticuerpo monoclonal especifico para un inhibidor de la coagulacion.
EA200000069A1 (ru) Способ получения 4-замещенных-1h-индол-3-глиоксамидов
JPS547595A (en) Base frame underground distribution pull-up tube
JPS522465A (en) Solar battery wrist watch
DK360981A (da) Fremgangsmaade til fremstilling af 4-lavere alkyl-3-phenoxypyridin-1-oxider
JPS52120711A (en) Remote test method for time division multiple unit
EA199800028A1 (ru) Винилсульфоксиды и способы их синтеза
JPS52134451A (en) Optical fibre connecting means
ES2073569T3 (es) Anticuerpo monoclonal contra la proteina c reactiva.
JPS52104939A (en) Connection method of optical fiber

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 361902

Country of ref document: ES